January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

The companies did not further specify the financial details. STX-478 is a PI3Kα inhibitor and aims to target the pathway in cancerous but not healthy cells, which the companies say would overcome ...

Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ:OKUR) with a Buy rating and a price target of $32.00.

Novartis won FDA approval for its PI3Kα inhibitor Piqray in 2019. Roche’s Itovebi joined the party late last year. Lilly’s attempt to follow its peers took a hit last year when it axed LOXO ...

“We are thrilled to present the first clinical data for our lead program, OKI-219, which is the only highly selective PI3Kα H1047R inhibitor molecule in the clinic,” said Nicholas ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX-478 ...